Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coviccine booster in adults 18-60
NCT06381843Completed
- Sponsor
- WestVac Biopharma
- Start
- Aug 2022
- Primary completion
- Mar 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial of recombinant COVID-19 (XBB) trimer protein vaccine in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by WestVac Biopharma. Primary endpoints: Incidence of adverse drug reactions, Geometric mean titer of specific neutralizing antibody against SARS-CoV-2 prototype strain and 1 more. Started Aug 2022; status: completed.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT06381843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06381843.